Sutro Biopharma (STRO) Receivables - Other (2017 - 2020)

Sutro Biopharma has reported Receivables - Other for 4 years, with the latest figure at $6.4 million in Q1 2020.

• Quarterly Receivables - Other rose 439.06% year-over-year to $6.4 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $6.4 million (up 439.06% YoY) and the FY2019 annual result came in at $1.0 million, up 9.49% from the prior year.
• Receivables - Other grew to $6.4 million in Q1 2020 per STRO's latest filing, from $1.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $6.4 million in Q1 2020 and troughed at $784000.0 in Q4 2017.
• A 4-year average of $1.9 million and a median of $1.1 million in 2019 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2019 and 2020: Receivables - Other increased 9.49% in 2019, then surged 439.06% in 2020.
• Over 4 years, Receivables - Other stood at $784000.0 in 2017, then grew by 22.32% to $959000.0 in 2018, then climbed by 9.49% to $1.0 million in 2019, then surged by 509.9% to $6.4 million in 2020.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.4 million, $1.0 million, and $2.1 million for Q1 2020, Q4 2019, and Q3 2019 respectively.